[Clinical benefits of stabilization after second-line chemotherapy in patients with metastatic colorectal cancer].
New innovative cytotoxic agents have proven active for treating patients with metastatic cancer who have failed first line 5FU based therapy, with sizeable objective response rates and a much higher rate of stabilization. The benefit of stabilization has not yet been well evaluated. A prospective multicentric study was carried out with 80 patients treated by second line chemotherapy for metastatic colorectal cancer. Tumor assessment and symptomatic status were reported at each cycle with a 4-month follow-up, allowing dynamic patient categorization per health state associated with the treatment. It appears that patients who are stabilized by chemotherapy have a quality of life profile comparable to that of responders, as opposed to patients with progressive disease. More patients experience improvement or stabilization of their quality of life, while they are stabilized versus progressive patients. Average number of days in hospital and hospital costs are cut down by three during stabilization as opposed to progressive disease. These results provide evidence that disease stabilization brings benefit to patients and reduces hospitalization.